Introduction
Migraine is a pathological condition characterised by crises of cephalic pain, at times accompanied by transient neurological and autonomic signs. Migraine attacks result from a complex cascade of events that initiate probably in the limbic structures and afterward spread to the cortex. Cortical spreading depression (SD), the neuronal event that is believed to cause the aura [1] , may contribute to the activation of primary afferent fibres of trigeminal ganglion which innervate the meningeal vessels [2] . This activation may cause the release of vasoactive peptides such as substance P, neurokinin A and calcitonin gene-related peptide in the trigeminal vascular bed [3, 4] . The abnormal synthesis of nitric oxide (NO) and vasodilation, ultimate events that cause the migraine attacks, may be related to the stimulation of endothelium and platelets by these vascular peptides [5, 6] . The pain sensation travels through the fibre endings of primary trigeminal afferents stretched on the vessel wall stimulated by NO to the trigeminal nucleus caudalis (TNC) [7] . In the TNC, the nociceptive signal is modulated by interneurons and descending inhibitory systems (serotoninergic and noradrenenergic) [8] . From there, the stimulus travels to the ventrobasal, posterior and medial thalamus nuclei and, as final destination, to the limbic and sensory cortex [9] .
Gamma-aminobutyric acid (GABA) and glutamate (Glu) are, respectively, the main inhibitory and excitatory neurotransmitters of the central nervous system (CNS) that modulate the neuronal excitability and pain threshold at many hierarchical levels of brain and spinal cord [10] .
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GABA and migraine
GABA is a neutral inhibitory aminoacid widely distributed throughout the CNS, which binds to GABA A and possibly GABA B receptors. GABA A receptor is a complex of five peptide chains that form a transmembrane chloride ion channel. GABA A receptor has specific sites for GABA binding and can be modulated by substances such as picrotoxin, barbiturates, bendodiazepines and anaesthetic steroids [12] . GABA B receptors are coupled to calcium or potassium ion channels via GPT binding proteins [13] . At spinal and trigeminonuclear levels GABA, released from the interneurons located in the superficial spinal dorsal horn (lamina I, II), reduces the excitability of nociceptive neurons through the stimulation of GABA A and GABA B receptors, mainly located on presynaptic terminals and possibly mediating presynaptic inhibition [14] . Pharmacological evidence suggests that GABA receptors play a role in the regulation of pain threshold in the TNC. In addition, GABA regulates cortical functions by circuits that modulate the activity of NMDA receptors post-synaptically [15] .
In 1975, Welch et al. [16] showed that GABA levels in the cerebrospinal fluid (CSF), not detectable in tension-type headache (TTH) or in migraine during headache-free periods, increased during migraine attacks. They suggested that the metabolism of GABA is deranged in migraine [16] . In a second biochemical study, GABA was measured in the platelets of 19 migraine patients, 27 chronic tension-type headache (CTH) patients and 21 control subjects [17] . The GABA levels in platelets were similar in migraine patients (during headache-free periods) and controls, whereas they were significantly elevated in CTH patients [17] . In another study, GABA was measured in the saliva of a large group of patients with migraine without aura (MO), both between and during attacks, in TTH patients and in controls [18] . The GABA saliva levels were high during MO attacks in comparison to interictal periods and to control subjects [18] . It is possible that the increase of GABA metabolism may be a compensatory beneficial process to limit migraine attacks and other primary headaches.
This hypothesis seems to be confirmed by pharmacological evidence. Valproate (2-propylpentanoic acid), a branched-chain fatty acid used in the treatment of several seizure types, reduced the frequency and severity of spontaneous migraine attacks in randomized controlled trials [19] [20] [21] . The effective dosage of valproate varies from 500 to 1000 mg daily, the highest dose being the most effective [22] . The effectiveness of valproate in migraine treatment is probably related to the inhibition of GABA aminotransaminase and to the activation of glutamic acid decarboxylase [19] . These enzymes block the catabolism and increase the synthesis of the neurotransmitter, respectively. Consequently, there is an increase of GABA availability in the gabaergic synaptic cleft and an enhancement of the relative inhibitory neurotransmission [19] . It is possible that the usefulness of valproate in the treatment of chronic daily headache derives from the same mechanism of action [23] .
Gabapentin is a new antiepileptic drug that may increase brain GABA levels. In one randomised, double-blind, placebo-controlled trial, 63 migraine patients were treated with a 1200-mg/day final dose of gabapentin. At the end of treatment, about half of the patients had a significant reduction in frequency and severity of their migraine attacks [24] .
Excitatory aminoacids and migraine
Glutamic and aspartic (Asp) acids are CNS excitatory neurotransmitters. In the brain, Glu and and Asp are taken up from the circulation or directly synthesized and catabolized in the neurons and glia. Glu and Asp may be involved in migraine pathogenesis, since an abnormal release of glutamate causes neuronal hyperexcitability and may be essential in the propagation of SD, the supposed pathophysiological process of the aura [25, 26] . Some biochemical and pharmacological evidence in favour of this hypothesis is presented. Currently, it is not possible to study "in vivo" Glu and Asp metabolism in the CNS. Platelets are considered a good neuronal model for studying Glu and Asp metabolism. In fact platelets, like neurons and glia, synthesize and take up Glu from the blood, store it in the dense organelles and release this aminoacid with the same calcium-dependent mechanism of neurons [27] . Platelet levels of Glu and Asp were measured in patients with migraine with aura (MA) or MO and in control subjects in two studies [28, 29] . Both studies showed that platelet Glu and Asp levels are significantly higher in MA sufferers, both during headache-free periods and even more during attacks, in comparison to MO patients and control subjects. If these anomalies are shared by the neurons of MA sufferers, elevated amounts of excitatory aminoacids are available and may be released upon stimulation [28, 29] .
Lamotrigine (6-[2,3-dichlorophenyl]-1,2,3 triazine-3,5-diamine) is an antiepileptic drug for the treatment of partial and generalized epilepsies. It acts by blocking voltage-sen-sitive sodium channels, leading to the inhibition of neuronal release of Glu [30, 31] . The consequent reduced excitatory neurotrasmission may be beneficial in the prevention of migraine attacks.
Lamotrigine has been used as a prophylactic drug in MO and MA sufferers in three studies [32] [33] [34] . In the first study, a 3-month double-blind, randomised, parallel-groups trial mainly concerning MO sufferers, a dose of 200 mg/day gave negative results [32] . This study suggests that lamotrigine is ineffective in the prophylactic treatment of MO. The aim of the other two open pilot trials [33, 34] was to treat only MA patients. Lamotrigine was effective in reducing the number of attacks in patients with frequent MA attacks. In the majority of patients, aura completely disappeared. The useful dose was 50-100 mg daily, lower than that used as antiepileptic treatment [33, 34] . Another antiglutamatergic drug, ketamine (given intranasally at the dosage of 25 mg) reduced the severity and duration of disabling auras in 5 of 11 patients affected by familial hemiplegic migraine [35] , offering, for the first time, a possible treatment option for severe and prolonged aura.
Conclusions
Biochemical and pharmacological evidence suggests that GABA and Glu play a significant role in migraine pathogenesis. The pharmacological modulation of metabolism of both neurotransmitters is a promising approach to improve migraine therapy. In particular, the studies presented here suggest that gabaergic drugs may be useful in MO and in chronic daily headache, whereas antiglutamatergic drugs are indicated to treat MA.
